Introduction
Penile cancer is a rare cancer in the United States, with an annual incidence of 1.2 cases per 100,000 people. 1 About 95% of penile cancers are of squamous-cell histologic subtype, with 40% to 60% of cases associated with human papilloma virus infection. [1] [2] [3] Although localized disease portends generally favorable outcomes, with 5-year cancer-specific survival approaching 81%, increasing locally advanced disease carries a grim prognosis, with 5 year cancerspecific survival decreasing from 79% to 89% for pN1 disease to less than 20% for pN3 disease. 1, 4, 5 While the presence of clinically palpable inguinal lymph nodes makes the existence of lymph node metastasis likely, the ability to accurately stage patients with clinically node-negative disease remains problematic. Between 20% and 25% of high-risk clinically node-negative patients will harbor occult nodal disease. 4, 6 Current modalities for assessment of lymph node involvement include computed tomographic (CT) scan, ultrasound with fine needle aspiration, 18 F-fluorodeoxyglucose ( 18 F-FDG) positron emission tomography (PET)/CT, magnetic resonance imaging (MRI), and dynamic sentinel lymph node biopsy; each of these techniques carries its own particular set of limitations. 4, 6 Therefore, a need remains to improve detection of occult nodal disease in order to improve risk stratification and limit morbidity in penile cancer. In contrast to penile cancer, PET/CT with newer radiotracers is considered a reliable technique for detection of recurrent prostate cancer. 7 While a variety of radiotracers are available, antie1-amino- 
Case Presentation
A 71-year-old man had a history of prostate cancer treated with open radical prostatectomy with pelvic lymph node dissection in 2005, followed by early biochemical recurrence treated with salvage radiotherapy, and second biochemical recurrence in 2013 treated with 12 months of androgen deprivation therapy, with subsequent undetectable prostate-specific antigen (PSA). He presented to our institution for establishment of care. Unfortunately his final prostate cancer pathology, operative report, and prior PSA values were unavailable.
At examination, the patient was found to have a palpable nodule on the right glans of his penis. Pelvic MRI revealed an 8 mm soft tissue nodule in the right glans without obvious invasion and no evidence of enlarged lymph nodes. He underwent cystoscopy with urethral lesion biopsy and incisional biopsy of the right glans mass in 2014. Pathology revealed invasive poorly differentiated carcinoma with squamous differentiation. He underwent partial penectomy of the distal glans and urethra, with final pathology showing poorly differentiated SCC with invasion of the corpus spongiosum (pT2) and lymphovascular invasion. Subsequent staging bilateral inguinal, femoral, superficial, and deep lymph node dissections were negative for disease, and he was placed on surveillance. During this time, his PSA increased to 3.17 ng/mL with negative staging according to technetium bone scan and MRI of the abdomen and pelvis. He continued with surveillance for both prostate and penile cancer.
His course was complicated by development of a recurrently infected vesicoperineal fistula requiring eventual cystectomy with Clinical Genitourinary Cancer February 2019 -e185 urinary diversion in February 2017. His PSA remained stable until a sharp rise to 10.7 ng/mL occurred in September 2017, with subsequent negative repeat MRI and bone scan. His PSA remained stable for a year until its subsequent increase to 13.2 ng/mL in January 2018, prompting evaluation with newly available 18 F-fluciclovine PET/CT (Figure 1 ). PET/CT was notable for a 2.2 Â 2.6 cm left inguinal lymph node with increased uptake. Percutaneous biopsy was performed; results were consistent with high-grade SCC. He underwent repeat inguinal lymphadenectomy on June 2018 that revealed a 20 mm poorly differentiated SCC in 1 of 2 nodes. Given his pN1 disease status, the decision was made to continue surveillance with physical examination and MRI every 6 months.
Discussion
To our knowledge, this is the first reported case of 18 F-fluciclovine PET/CT detecting an inguinal lymph node positive for penile SCC. 18 F-fluciclovine is a nonnatural amino acid that primarily targets the ASCT2 amino acid transporter for cellular uptake into prostate cancer cells as well as the LAT1 transporter. 7, 8 Additionally, recent studies have shown increased expression of ASCT2 and/or LAT1 in squamous-cell tongue, laryngeal, and esophageal cancers, implying that there may be a role for 18 F-fluciclovine PET/CT in not only penile SCC but also in many other squamous-cell malignancies. [9] [10] [11] Furthermore, studies of 18 F-fluciclovine PET/CT are exploring its utility in melanoma, brain, and breast cancer. 18 F-fluciclovine's minimal elimination by the kidneys during a typical imaging time course makes it ideal in the study of pelvic malignancies. 7, [12] [13] [14] Since its development, 18 F-fluciclovine PET/CT has been approved by the US Food and Drug Administration in the imaging of recurrent prostate cancer. 7, 8 However, to our knowledge, no studies or reports have demonstrated the ability of 18 F-fluciclovine to detect locally advanced penile cancer. Management of penile cancer depends on appropriate risk stratification and identification of individuals with locally advanced disease who may benefit from inguinal lymphadenectomy. 4, 6, 15 Studies have shown that between 20% and 25% of patients presenting with penile cancer will harbor occult metastatic disease. 4, 6 However, the decision to perform lymphadenectomy has to be carefully considered, with appropriate patients identified, as it carries considerable risk of morbidity. 4 Currently, the reference standard for staging the disease of patients with clinically nodenegative disease is dynamic sentinel lymph node biopsy, with a sensitivity of 88%; however, this requires an invasive procedure, with up to 10% risk of complications, and has had mixed results outside of large specialized European centers. 4, 6, 15 As such, staging bilateral inguinofemoral lymphadenectomy is the most common intervention in the United States. In regards to PET/CT imaging, 18 F-FDG PET/CT has been used, but with a limited sensitivity of 57% in patients with nodenegative disease, thus likely restricting its utility to quantifying disease burden and treatment response in patients with node positive disease. 4 18 F-fluciclovine PET/CT may represent a new minimally invasive modality for the detection of locally advanced penile cancer in patients harboring occult disease. However, further studies are needed to better understand the mechanisms behind 18 F-fluciclovine uptake in penile cancer as well as to better delineate the performance of 18 F-fluciclovine PET/CT compared to traditional methods for detecting nodal disease in penile cancer.
Conclusion
Penile SCC often harbors occult locally advanced disease.
18
F-fluciclovine PET/CT has shown success in identifying recurrent disease in prostate cancer, with acceptable specificity and sensitivity.
Here we report what is to our knowledge the first case of 18 F-fluciclovine PET/CT identifying a positive lymph node for recurrent squamous-cell penile cancer. 18 F-fluciclovine PET/CT may represent a potentially new avenue for identification of occult locally advanced disease in penile cancer, but further studies need to be undertaken.
